Results 71 to 80 of about 3,554 (229)

Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations [PDF]

open access: yes, 2015
Objective: The studies that have extensively evaluated the relation between adipokines and metabolic parameters in acromegaly treatment are quite discordant. We aimed to evaluate and correlate a set of selected adipokines, known to have a metabolic role,
Amato, M.   +3 more
core   +1 more source

Transformative Impact of Nanocarrier‐Mediated Drug Delivery: Overcoming Biological Barriers and Expanding Therapeutic Horizons

open access: yesSmall Science, Volume 4, Issue 11, November 2024.
The development of drug delivery systems is revolutionizing therapeutic progress by ensuring precise targeting and optimal drug concentrations. Nanocarriers, with their customizable properties and controlled release, overcome biological barriers to improve treatment outcomes. This study explores the potential of integrating artificial intelligence with
Minhye Kim   +4 more
wiley   +1 more source

Pituitary hormones are specifically expressed in trigeminal sensory neurons and contribute to pain responses in the trigeminal system

open access: yesScientific Reports, 2021
Trigeminal (TG), dorsal root (DRG), and nodose/jugular (NG/JG) ganglia each possess specialized and distinct functions. We used RNA sequencing of two-cycle sorted Pirt-positive neurons to identify genes exclusively expressing in L3–L5 DRG, T10-L1 DRG, NG/
Anahit H. Hovhannisyan   +13 more
doaj   +1 more source

Pregnancy and acromegaly [PDF]

open access: yes, 2016
Introduction: Acromegaly is a rare disorder in which, due to the high incidence of secondary hypogonadism, pregnancies are relatively rare. However, some women with acromegaly do get pregnant, which brings along questions about medication, complications ...
Lely, A-J. (Aart-Jan) van der   +2 more
core   +1 more source

Pegvisomant in acromegaly: an update [PDF]

open access: yesJournal of Endocrinological Investigation, 2017
In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety.We here reviewed the emerging aspects of the use of PEG in clinical practice in the light of the most recent literature.
Giustina, A   +13 more
openaire   +7 more sources

Acromegaly management in the Nordic countries: A Delphi consensus survey

open access: yesClinical Endocrinology, Volume 101, Issue 3, Page 263-273, September 2024.
Abstract Objective Acromegaly is associated with increased morbidity and mortality if left untreated. The therapeutic options include surgery, medical treatment, and radiotherapy. Several guidelines and recommendations on treatment algorithms and follow‐up exist. However, not all recommendations are strictly evidence‐based. To evaluate consensus on the
Mai C. Arlien‐Søborg   +47 more
wiley   +1 more source

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

open access: yesBMC Endocrine Disorders, 2018
Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored.
A. Ciresi   +3 more
doaj   +1 more source

Treatment adherence to pegvisomant (somavert®) in Spain: PEGASO study [PDF]

open access: yes, 2017
This is a pre-copyedited, author-produced version of an article accepted for publication in Endocrine Reviews following peer review.
Aller, J.   +7 more
core  

Improving quality of life in patients with pituitary tumours [PDF]

open access: yes, 2017
Evaluation of health-related quality of life (QoL) in people with pituitary tumours has received much attention over the last 10-15 years. Most of them show impaired QoL, but little is known about how to prevent impairment or how to improve QoL.
Crespo, Iris   +5 more
core   +1 more source

Identification of common mechanisms and biomarkers of atrial fibrillation and heart failure based on machine learning

open access: yesESC Heart Failure, Volume 11, Issue 4, Page 2323-2333, August 2024.
Abstract Aims Atrial fibrillation (AF) is the most common arrhythmia. Heart failure (HF) is a disease caused by heart dysfunction. The prevalence of AF and HF were progressively increasing over time. The co‐existence of AF and HF presents a significant therapeutic challenge.
Zhijun Zhang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy